
Sign up to save your podcasts
Or


In the first episode of our second season, we chatted with Dr. Kiersten Stead, Managing Partner at DCVC Bio. Our conversation focused on computational drug discovery, her latest investments, and the keys to company creation in this burgeoning space.
DCVC Bio is the bio-focused arm of DCVC, a VC with $3B+ in AUM focused on deep-tech investing, where Kiersten invests in therapeutics, agriculture, and synthetic biology companies with a deep-tech advantage.
By Wharton Health Care5
22 ratings
In the first episode of our second season, we chatted with Dr. Kiersten Stead, Managing Partner at DCVC Bio. Our conversation focused on computational drug discovery, her latest investments, and the keys to company creation in this burgeoning space.
DCVC Bio is the bio-focused arm of DCVC, a VC with $3B+ in AUM focused on deep-tech investing, where Kiersten invests in therapeutics, agriculture, and synthetic biology companies with a deep-tech advantage.